Pharmaceutical Consulting Services

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate fund raising activities to support its next steps. Alacrita had previously been commissioned by an investor to conduct due diligence on the company for an earlier funding round. This time, we were approached directly by the pharma company to perform an updated due diligence exercise and develop an independent report of the company’s progress for other potential investors.

Solution: Our neurology expert reviewed all of the available clinical data for the company’s lead product and developed an opinion on the strength of the data and the likelihood of approval in each indication. Using these outputs, our market analysis expert quantified the commercial potential in each indication. We presented our findings to the pharma company, which subsequently used the output of the due diligence to engage with potential investors.

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a particular area defined as disorders of one of the major organ systems and has been very active in licensing and M&A over the past four years.

Solution: The client established a framework agreement with Alacrita facilitating the commissioning of a series of due diligence assignments over the course of each year. The typical process involves Alacrita identifying appropriately qualified experts from its network for each DD situation who then interact with the relevant members of the client's internal team. Over the course of any particular year, Alacrita conducts three to five assessments for the client, ranging in size depending on the development stage of the target asset(s).

Challenge: A European clinical-stage pharma company was developing a recombinant protein for multiple immune-driven indications and required support in shaping its future business strategy. Alacrita was commissioned to conduct an independent strategic review of the company, identify any short and long-term value-adding activities for its programs and identify potential future pharma partners.

Solution: Alacrita´s specialist team conducted a reality check on the target company´s activities to date, analyzing the biological target robustness across different indications, proof of concept data from each program and the current valuation assumptions.

From this we identified several activities and direction changes that could add immediate value to the company and improve attractiveness to future pharma partners.